Butterfly (BFLY) Q1 2026 Earnings Transcript

Butterfly Network reported Q1 revenue of $26.5 million, up 25% year over year, with gross margin expanding to 69% from 63% and adjusted EBITDA loss improving to $6.1 million from $9.1 million. Management reaffirmed full-year 2026 guidance for revenue of $117 million-$121 million and adjusted EBITDA loss of $21 million-$25 million, while highlighting new FDA clearance for an AI gestational-age tool, rapid Butterfly Embedded growth (+147%), and a first enterprise Compass AI contract. The call also pointed to strengthening medical-school adoption, Home and Community Care commercialization in 2H26, and a growing partner pipeline that could support further upside.

Analysis

The setup is better than the headline suggests because the company is shifting from a single-product hardware story toward a three-legged platform with increasingly diversified monetization: recurring software, embedded licensing, and services tied to care delivery. That mix matters because it should lower revenue volatility and improve valuation multiple support if the market starts treating BFLY less like a device vendor and more like a software-enabled platform with optionality in adjacent workflows. The gross margin inflection is likely the bigger signal than the revenue beat: if that mix persists, operating leverage can accelerate even without hero assumptions on unit growth.

The second-order winner is the ecosystem around Butterfly’s clinical workflow, not just Butterfly itself. AI partners, cloud/security providers, and any health-system reseller channel may see faster adoption because the company is now using regulatory wins as a distribution wedge; once an AI application is cleared and embedded into an installed base, the marginal cost of rollout collapses. The underappreciated catalyst is that enterprise procurement is now getting easier: cybersecurity certifications and public-sector pathway access can shorten sales cycles by quarters, which matters more than the near-term revenue contribution from any single contract.

The main risk is execution timing rather than demand. The market is being asked to underwrite multiple 2H26 and 2027 catalysts simultaneously, so any slippage in Home, partner launches, or enterprise conversion would compress the story quickly. There is also valuation fragility if investors conclude the recent margin improvement is mix-driven and not durable; in that case, the stock can re-rate sharply despite top-line growth because this is still a cash-burning business with multiple “promises” not yet cash flow.

Consensus appears to be underpricing the embedded optionality but overpricing near-term monetization. The most interesting read-through is that regulatory and technical validation can create a moat that competitors in handheld ultrasound cannot quickly replicate, but it will take 6-12 months of evidence before the market awards that premium. In the meantime, the stock is likely to trade on whether every new announcement converts into signed, revenue-bearing contracts rather than narrative alone.

Key Decisions for Investors

• Go long BFLY on post-earnings strength only if the stock holds above the prior breakout level for 3-5 sessions; use a 3-6 month horizon for a move toward a higher multiple if software/Embedded convert into follow-through bookings.
• Buy a call spread on BFLY with 6-9 month tenor to express upside from 2H26 catalyst realization while limiting downside if Home or Embedded timing slips; the key risk is volatility crush if the market deems guidance conservative but credible.
• Pair long BFLY / short a legacy handheld ultrasound peer basket over 3-6 months: the trade favors names with semiconductor/software leverage and better margin trajectory versus hardware-only incumbents facing slower regulatory optionality.
• If BFLY rallies hard on the FDA/Embedded narrative, trim into strength and keep a residual position only if enterprise contract wins continue; this is a story that can re-rate fast but also mean-revert quickly on execution misses.
• Avoid chasing OKYO as a direct trade on the EU lead-exemption commentary; the regulatory signal is supportive for Butterfly’s thesis, but near-term fundamental capture is much more likely to accrue to BFLY than to the regulator-adjacent ticker.